Tokyo, Dec. 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060067) titled 'Safety and Efficacy of Fiducial Marker and Hydrogel Spacer Placement in Carbon-Ion Radiotherapy for Prostate Cancer' on Dec. 12.
Study Type:
Observational
Primary Sponsor:
Institute - National Institutes for Quantum Science and Technology, QST Hospital
Condition:
Condition - prostate cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the safety of fiducial marker and hydrogel spacer placement in carbon-ion radiotherapy for prostate cancer.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male
Key inclusion criteria - Patients who underwent carbon-ion radiotherapy for prostate cancer at our institution between April 2018 and August 2025
Key exclusion criteria - Cases in which the patient or their representative refused the use of data for this study.
Cases with incomplete or missing data.
Target Size - 2500
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 10 Month 10 Day
Anticipated trial start date - 2025 Year 10 Month 10 Day
Last follow-up date - 2030 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068277
Disclaimer: Curated by HT Syndication.
